Google’s healthcare API has its ‘first and only’ supplier of MFT software

Two weeks after Google Cloud opened its healthcare application program interface (API) to support providers during the COVID-19 crisis, Coviant Software is announcing it has become the first and only supplier of managed file transfer (MFT) software to fully support the API for data exchange.

In making the announcement, Coviant says healthcare data stored on Google’s HIPAA-compliant cloud platform can be easily integrated into data processing, analytics and AI.

Coviant CEO Greg Hoffer adds that, when the company learned Google Cloud’s healthcare API can play a key role in the management, analytics and exchange of important and sensitive healthcare data, “we quickly extended our solution to make integration into the Google Cloud Healthcare API as simple as ticking a box and filling in a few fields.”

Hoffer expounds on the point in a blog post.

“Secure sharing of healthcare data is an important step in improved diagnosis and prevention of disease,” he writes. “Extending the [Coviant] platform to support both Google Cloud Storage for low-cost, scalable and secure file storage and Google Cloud Healthcare API makes working with healthcare data more effective and efficient.”

For more on Google Cloud’s healthcare API, click here.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.